Table 1

Rates of hospital PCR-confirmed COVID-19 cases in patients with different rheumatic diseases

nCOVID-19 prevalence % (CI)OR (CI) versus reference§Median age of cases (IQR)Sex (female, %)
Reference population2 899 9350.58 (0.57 to 0.59)55(43-69)†44†
All rheumatic diseases26 1310.76 (0.66 to 0.87)1.32 (1.15–1.52)*65 (53–78)*56
Inflammatory arthritis19 9750.63 (0.53 to 0.75)1.06 (0.0.91–1.30)‡63 (53–75)*50
 Arthritis csDMARD75580.53 (0.38 to 0.72)1.10 (0.80–1.50)‡69 (52–79)*39
 Arthritis tsDMARD/bDMARD58020.94 (0.71 to 1.22)1.60 (1.23–2.10)**60 (51–70)***53
RA10 9270.57 (0.44 to 0.73)0.98 (0.76–1.26)‡67 (56–79)*56
PsA47770.57 (0.37 to 0.82)0.97 (0.67–1.43)‡57 (51–78)‡48
SpA42680.89 (0.63 to 1.22)1.54 (1.11–2.13)***59 (49–69)‡43
AI/IMID47811.11 (0.83 to 1.45)1.92 (1.47–2.53)*60 (51–73)***68
 AI/IMID non-SLE25281.54 (1.10 to 2.10)2.69 (1.96–3.69)*60 (54–76)*65
 SLE22530.62 (0.34 to 1.04)1.07 (0.63–1.80)‡51 (42–66)*77
PMR-CGA13781.45 (0.89 to 2.23)2.53 (1.62–3.93)*84 (75–86)**57
  • *P<0.0001, **p<0.001, ***p<0.01.

  • †Calculated in a subset of reference population cases (n 3,800).

  • ‡Non-significant difference.

  • §Odds ratio (OR) with 95% confidence intervals (CI), and all comparisons were between each group and the reference population.

  • AI/IMID, autoimmune or immune-mediated disease; bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional-synthetic disease-modifying antirheumatic drug; PMR-CGA, polymyalgia rheumatica or giant cell arteritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; tsDMARD, targeted-synthetic disease-modifying antirheumatic drug.